Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;25(4):801-807.
doi: 10.1093/annonc/mdt574. Epub 2014 Feb 26.

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

J B Vermorken  1 , A Psyrri  2 , R Mesía  3 , F Peyrade  4 , F Beier  5 , B de Blas  6 , I Celik  6 , L Licitra  7
Affiliations

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

J B Vermorken et al. Ann Oncol. 2014 Apr.

Abstract

Background: Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status.

Patients and methods: Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays.

Results: Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients.

Conclusion: The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.

Keywords: cetuximab; human papillomavirus; p16; recurrent and metastatic; squamous cell carcinoma of the head and neck.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Overall survival according to treatment arm and tumor p16 expression. (B) Overall survival according to treatment arm and tumor HPV status. (C) Progression-free survival according to treatment arm and tumor p16 expression. (D) Progression-free survival according to treatment arm and tumor HPV status.
See this image and copyright information in PMC

Comment in

References

    1. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101:412–423. - PubMed
    1. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35:747–755. - PubMed
    1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. - PMC - PubMed
    1. Isayeva T, Li Y, Maswahu D, et al. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012;6(Suppl 1):S104–S120. - PMC - PubMed
    1. Vermorken J, Stöhlmacher J, Oliner K, et al. Safety and efficacy of panitumumab (pmab) in HPV positive (+) and HPV negative (−) recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): analysis of the phase 3 SPECTRUM trial. Eur J Cancer. 2011;47(Suppl 2):13 LBA.

Publication types

MeSH terms

Substances

LinkOut - more resources